Objects of the present invention are the compounds of formula (I)
their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.
Novel oxazoles, their manufacture and use as pharmaceutical agents
申请人:Bossenmaier Birgit
公开号:US20050038091A1
公开(公告)日:2005-02-17
The present invention relates to novel oxazoles of formula (I)
their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I), wherein X represents CH
2
or O; R
1
represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C
1-4
)alkyl, (C
1-4
)alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R
2
represents (C
1-4
)alkyl, (C
1-4
)alkoxy, (C
2-4
)alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR
5
R
6
or cyclopropyl; R
3
represents (C
1-4
)alkyl, (C
1-4
)alkoxy-methyl or halogen; R
4
represents (C
1-4
)alkyl; R
5
represents hydrogen or (C
1-4
)alkyl; and R
6
represents hydrogen or (C
1-4
)alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.
The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I), wherein X represents CH2 or O; R1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R2 represents (C1-4)alkyl, (C1-4)alkoxy, (C2-4)alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR5R6 or cyclopropyl; R3 represents (C1-4)alkyl, (C1-4)alkoxy-methyl or halogen; R4 represents (C1-4)alkyl; R5 represents hydrogen or (C1-4)alkyl; and R6 represents hydrogen or (C1-4)alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.